Protagonist Therapeutics Unveils Promising Results for Icotrokinra in Psoriasis Treatment

Protagonist Therapeutics has announced significant findings from its Phase 3 ICONIC clinical program for icotrokinra, a novel oral treatment for moderate-to-severe plaque psoriasis. Data revealed that nearly half of the patients achieved completely clear skin within 24 weeks. Notably, 46% reached an Investigator's Global Assessment (IGA) score of 0, indicating fully clear skin, while 40% achieved a 100% improvement in the Psoriasis Area and Severity Index (PASI).

The clinical studies demonstrated icotrokinra's superiority over deucravacitinib, a competing treatment, in achieving key endpoints. These outcomes support the initiation of a head-to-head trial comparing icotrokinra to ustekinumab, an injectable biologic, to further explore its efficacy.

Results showed a comparable safety profile to placebo, with no new adverse events reported. Protagonist Therapeutics plans to continue its clinical program to establish icotrokinra as a first-line systemic therapy for psoriasis treatment.